<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-21T11:37:10+08:00</updated>
  <subtitle>世事洞明皆学问，人情练达即文章</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>RNAi疗法：走出至暗时刻，全新时代已来</title>
    <updated>2020-12-21T07:45:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/i-bEbcvfT12EQ-Rs1EBBzw</id>
    <link href="https://mp.weixin.qq.com/s/i-bEbcvfT12EQ-Rs1EBBzw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA发出完全回复信！诺华重磅RNAi降脂药inclisiran美国上市推迟</title>
    <updated>2020-12-21T07:45:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/UMQjiWhCWe5J7dKoU8hANA</id>
    <link href="https://mp.weixin.qq.com/s/UMQjiWhCWe5J7dKoU8hANA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>华领医药公布首创降糖药52周数据，多扎格列艾汀商业化在即</title>
    <updated>2020-12-21T07:45:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/BpUrU23kezCdRK8V7xZezA</id>
    <link href="https://mp.weixin.qq.com/s/BpUrU23kezCdRK8V7xZezA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>前线治疗获批上市！FDA批准XPOVIO®用于治疗接受过至少一线治疗的多发性骨髓瘤患者</title>
    <updated>2020-12-21T07:45:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/bITabWznK4OjzcFFSBf2vQ</id>
    <link href="https://mp.weixin.qq.com/s/bITabWznK4OjzcFFSBf2vQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年，这19家中国公司获得35项FDA孤儿药资格</title>
    <updated>2020-12-20T08:59:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/v1MBhYlmo3AMIzEKfrEeTg</id>
    <link href="https://mp.weixin.qq.com/s/v1MBhYlmo3AMIzEKfrEeTg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>高筑墙、广积粮 ! 加科思打造KRAS王国</title>
    <updated>2020-12-19T08:22:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/6fJdo3tFVLAhC4l2GD_MLg</id>
    <link href="https://mp.weixin.qq.com/s/6fJdo3tFVLAhC4l2GD_MLg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚组分析，失败临床研究的一线生机？</title>
    <updated>2020-12-19T08:22:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/ykie4JfLTnk1Jy930M7nuw</id>
    <link href="https://mp.weixin.qq.com/s/ykie4JfLTnk1Jy930M7nuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>生物分析专栏 | 前体药物的生物分析</title>
    <updated>2020-12-18T07:55:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/6N2gnMHMA2RF_xAjphOCJA</id>
    <link href="https://mp.weixin.qq.com/s/6N2gnMHMA2RF_xAjphOCJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Cell：癌症免疫治疗新靶点——PHD3</title>
    <updated>2020-12-18T07:55:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/YAeB5ykBHL_9AgF8nrnWdg</id>
    <link href="https://mp.weixin.qq.com/s/YAeB5ykBHL_9AgF8nrnWdg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PD-1医保谈判尘埃落定：价格结果秘而不宣，产能比拼枕戈待旦</title>
    <updated>2020-12-17T07:38:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/oEcjopAMg8fY8KMIk3pogg</id>
    <link href="https://mp.weixin.qq.com/s/oEcjopAMg8fY8KMIk3pogg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>索马鲁肽治疗阿尔茨海默病！诺和诺德直接启动3700人IIIa期试验</title>
    <updated>2020-12-17T07:38:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/rgl3gpeAmXzw9fdKkgdfKQ</id>
    <link href="https://mp.weixin.qq.com/s/rgl3gpeAmXzw9fdKkgdfKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>华润三九获得Oncoceutics脑胶质瘤创新药物ONC201大中华区独家授权</title>
    <updated>2020-12-17T07:38:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/kv9W8r52SsVWI4hbHhtlvg</id>
    <link href="https://mp.weixin.qq.com/s/kv9W8r52SsVWI4hbHhtlvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美诺华：原料药企业的“一横一纵”扩张战略</title>
    <updated>2020-12-16T07:41:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/O5WPk7yl6XSTZzxt0oj5dA</id>
    <link href="https://mp.weixin.qq.com/s/O5WPk7yl6XSTZzxt0oj5dA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床</title>
    <updated>2020-12-16T07:41:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/CxImEcMs6EHTzC7WPU7zjQ</id>
    <link href="https://mp.weixin.qq.com/s/CxImEcMs6EHTzC7WPU7zjQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>鸿运华宁郑州生产基地启动，为单抗药物上市及国际化做准备</title>
    <updated>2020-12-16T07:41:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/M9_g0LlV7yH_vE2SlFAI_Q</id>
    <link href="https://mp.weixin.qq.com/s/M9_g0LlV7yH_vE2SlFAI_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选最新版NCCN®多发性骨髓瘤诊疗指南</title>
    <updated>2020-12-16T07:41:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/CZ7qwvpiUNKGGw0aT85n0A</id>
    <link href="https://mp.weixin.qq.com/s/CZ7qwvpiUNKGGw0aT85n0A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PROTAC再获积极疗效数据，Arvinas股价暴涨95%</title>
    <updated>2020-12-15T07:23:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/5sZ_mGiUcF_OhJjir1o0Tw</id>
    <link href="https://mp.weixin.qq.com/s/5sZ_mGiUcF_OhJjir1o0Tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康69亿美元收购的DS-8201，临床试验设计有何奥秘？</title>
    <updated>2020-12-15T07:23:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/Um-9Vs2_r4mtfhtkYc1b6g</id>
    <link href="https://mp.weixin.qq.com/s/Um-9Vs2_r4mtfhtkYc1b6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>绿叶制药抗抑郁新药LY03005完成中国III期临床主要疗效指标观察</title>
    <updated>2020-12-15T07:23:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/QaIZetsib1FZa8v5MbWx_A</id>
    <link href="https://mp.weixin.qq.com/s/QaIZetsib1FZa8v5MbWx_A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康方生物CTLA-4和Keytruda联合用药治疗1L NSCLC I/II期临床效果喜人，计划开展III期临床</title>
    <updated>2020-12-15T07:23:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/scWRKxxxJFkvLtQysApJOw</id>
    <link href="https://mp.weixin.qq.com/s/scWRKxxxJFkvLtQysApJOw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>